CRSPR at SupportWeekly Chart of CRISPR.
At a support( demand zone).
As soon as it takes of 138 stock will come under bullish territory.
Long CRSPR.
Remember Weekly Charts are used for Investmet Duration greater than 3 months.
−1.640CHF
−129.33 MCHF
312.53 MCHF
80.46 M
About CRISPR THERAPEUTIC
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Employees (FY)
407
Founded
2013
ISIN
CH0334081137
FIGI
BBG00LVD6DC2
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1CG is 52.283 CHF — it has decreased by 0.30% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CRISPR THERAPEUTIC stocks are traded under the ticker 1CG.
CRISPR THERAPEUTIC is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
1CG stock is 0.30% volatile and has beta coefficient of 2.53. Check out the list of the most volatile stocks — is CRISPR THERAPEUTIC there?
One year price forecast for CRISPR THERAPEUTIC has a max estimate of 181.410 CHF and a min estimate of 27.348 CHF.
1CG earnings for the last quarter are −1.29 CHF whereas the estimation was −1.82 CHF which accounts for 29.12% surprise. Estimated earnings for the next quarter are 0.06 CHF. See more details about CRISPR THERAPEUTIC earnings.
CRISPR THERAPEUTIC revenue for the last quarter amounts to 0 CHF despite the estimated figure of 10.88 M CHF. In the next quarter revenue is expected to reach 118.67 M CHF.
Yes, you can track CRISPR THERAPEUTIC financials in yearly and quarterly reports right on TradingView.
1CG stock has fallen by 14.10% compared to the previous week, the month change is a 17.06% fall, over the last year CRISPR THERAPEUTIC has showed a 5.26% increase.
1CG net income for the last quarter is 75.22 M CHF, while the quarter before that showed −102.68 M CHF of net income which accounts for 173.26% change. Track more CRISPR THERAPEUTIC financial stats to get the full picture.
Today CRISPR THERAPEUTIC has the market capitalization of 4.30 B, it has decreased by 1.70% over the last week.
No, 1CG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 1CG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTIC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTIC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTIC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTIC stock shows the strong sell signal. See more of CRISPR THERAPEUTIC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CRISPR THERAPEUTIC future price: according to them, 1CG price has a max estimate of 181.41 CHF and a min estimate of 27.35 CHF. Read a more detailed CRISPR THERAPEUTIC forecast: see what analysts think of CRISPR THERAPEUTIC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTIC EBITDA is −150.94 M CHF, and current EBITDA margin is −54.61%. See more stats in CRISPR THERAPEUTIC financial statements.